De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Integral Diagnostics Beheer

Beheer criteriumcontroles 2/4

De CEO Integral Diagnostics' is Ian Kadish, benoemd in May2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.24M, bestaande uit 66.3% salaris en 33.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde A$ 1.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.9 jaar en 2.3 jaar.

Belangrijke informatie

Ian Kadish

Algemeen directeur

AU$1.2m

Totale compensatie

Percentage CEO-salaris	66.3%
Dienstverband CEO	7.4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ian Kadish's beloning veranderd ten opzichte van Integral Diagnostics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$825k	-AU$61m
Mar 31 2024	n/a	n/a	-AU$59m
Dec 31 2023	n/a	n/a	-AU$58m
Sep 30 2023	n/a	n/a	-AU$16m
Jun 30 2023	AU$1m	AU$794k	AU$25m
Mar 31 2023	n/a	n/a	AU$23m
Dec 31 2022	n/a	n/a	AU$21m
Sep 30 2022	n/a	n/a	AU$18m
Jun 30 2022	n/a	AU$781k	AU$15m
Mar 31 2022	n/a	n/a	AU$18m
Dec 31 2021	n/a	n/a	AU$22m
Sep 30 2021	n/a	n/a	AU$26m
Jun 30 2021	AU$2m	AU$736k	AU$31m
Mar 31 2021	n/a	n/a	AU$32m
Dec 31 2020	n/a	n/a	AU$32m
Sep 30 2020	n/a	n/a	AU$28m
Jun 30 2020	AU$1m	AU$635k	AU$23m
Mar 31 2020	n/a	n/a	AU$22m
Dec 31 2019	n/a	n/a	AU$21m
Sep 30 2019	n/a	n/a	AU$21m
Jun 30 2019	AU$876k	AU$549k	AU$21m
Mar 31 2019	n/a	n/a	AU$19m
Dec 31 2018	n/a	n/a	AU$17m
Sep 30 2018	n/a	n/a	AU$16m
Jun 30 2018	AU$711k	AU$489k	AU$15m

Compensatie versus markt: De totale vergoeding ($USD 858.35K ) Ian } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 899.18K ).

Compensatie versus inkomsten: De vergoeding van Ian is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ian Kadish (61 yo)

7.4yrs

Tenure

AU$1,243,752

Compensatie

Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Kadish	CEO, MD & Director	7.4yrs	AU$1.24m	0.25% A$ 1.8m
Jacqueline Milne	Executive Director	4.9yrs	AU$1.15m	0.011% A$ 77.8k
Scott Paterson	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Julian Gully	Chief Information Officer	5.1yrs	geen gegevens	geen gegevens
John Merity	Company Secretary	less than a year	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van IDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Kadish	CEO, MD & Director	no data	AU$1.24m	0.25% A$ 1.8m
Jacqueline Milne	Executive Director	4.9yrs	AU$1.15m	0.011% A$ 77.8k
Raelene Murphy	Independent Non-Executive Director	7yrs	AU$140.53k	0.013% A$ 95.6k
Andrew Fay	Independent Non-Executive Director	2.3yrs	AU$137.50k	0.036% A$ 262.7k
Ingrid Player	Independent Non-Executive Director	1.2yrs	AU$111.22k	0.015% A$ 108.1k
James Hall	Independent Non-Executive Chairman	1.1yrs	AU$168.37k	0.065% A$ 468.8k

2.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IDX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Integral Diagnostics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Integral Diagnostics Limited Appoints Toby Hall as Director

Recent updates

Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023)

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd